Antimicrobial-coated/bonded and -impregnated intravascular catheters

OBJECTIVE: To review the literature regarding the prevention of catheter co lonization and catheter-related bloodstream infections (CRBIs) with the use of antimicrobial-coated/bonded and -impregnated intravascular catheters. DATA SOURCES: Primary and review English-language literature were identifie d using MEDLINE (1966-September 2000) pertaining to the key terms antibioti c, antimicrobial, antiseptic, silver, and bonded, coated, impregnated cathe ters. In addition, textbooks and relevant reference lists were reviewed. DATA EXTRACTION: All articles identified through the data sources were eval uated. Information deemed relevant to the Objectives of the review was incl uded. DATA SYNTHESIS: Significant morbidity and mortality are associated with the development of CRBIs. Preventative measures such as modification of these catheters with antimicrobial coating/bonding have produced varying results. Trials evaluating cefazolin, teicoplanin, vancomycin, silver, and chlorhex idine-silver sulfadiazine (C-SS) used for coated/bonded intravascular cathe ters have not demonstrated a consistent decrease in the incidence of CRBIs. However, a meta-analysis of trials evaluating C-SS intravascular catheters demonstrated a statistically significant reduction in CRBIs. A larger redu ction in CRBIs has been reported with minocycline-rifampin (M-R) versus C-S S intravascular catheters. Use of the M-R and C-SS catheters may result in a cost savings of $100 million and reduce as many as 12 000 CRBI-related de aths annually when used short term (<7 d). CONCLUSIONS: When used for short-term catheterization, M-R catheters appear to be superior to the currently available C-SS catheters at preventing CRB Is. Significant cost savings and reduction in mortality can be anticipated with the use of M-R catheters.